JANNA CRAYCHEE: Open Payments
NPI 1780233411 · CORONADO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,151 in 55 payments from 14 companies in 2025. Trend: 2023 $1,584 · 2024 $1,581 · 2025 $2,151
Food & beverage: $1,571Travel & lodging: $581
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation | 5 | $941 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $253 |
| ABBVIE INC. | 9 | $161 |
| Janssen Biotech, Inc. | 6 | $121 |
| Gilead Sciences, Inc. | 1 | $118 |
| Regeneron Healthcare Solutions, Inc. | 4 | $109 |
| Madrigal Pharmaceuticals | 5 | $99 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| Celltrion USA Inc. | 3 | $71 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
Products named: General - Therapies, ENTYVIO, LINZESS, DUPIXENT, TREMFYA, REZDIFFRA, XIFAXAN, VEGZELMA.
Industry payments across CA — which companies pay providers there.
